Home > Oncology > ASCO 2021 > Genitourinary Cancers > Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC

Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC

Presented By
Dr Karim Fizazi , Institut Gustav Roussy, France
Conference
ASCO 2021
Trial
Phase 3, PEACE-1
First results from the phase 3 PEACE-1 trial showed that adding abiraterone to androgen deprivation therapy (ADT) plus docetaxel significantly improved progression-free survival in patients who present with de novo metastatic castration-sensitive prostate cancer (mCSPC), without meaningful added short-term toxicity. Historically, ADT was the standard of care for men with mCSPC. Since 2015, combining ADT with either docetaxel, novel hormonal therapies (abiraterone, enzalutamide), or radiotherapy to the primary tumour has shown to improve overall survival and, thus, became the new standard of care [1-4]. However, it was unknown whether combining these new treatments on top of ADT further increments outcomes. The primary goal of the PEACE-1 trial (NCT01957436) is to evaluate the efficacy and safety of the addition...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on